fenesa 200 mg/1 tableta filmom obložena tableta
zentiva pharma d.o.o. - sorafenib - filmom obložena tableta - 200 mg/1 tableta - 1 filmom obložena tableta sadrži: 200 mg sorafeniba (u obliku sorafenib tosilata)
fenesa 200 mg/1 tableta filmom obložena tableta
zentiva pharma d.o.o. - sorafenib - filmom obložena tableta - 200 mg/1 tableta - 1 filmom obložena tableta sadrži: 200 mg sorafeniba (u obliku sorafenib tosilata)
gemcitabin ebewe 1000mg/100ml koncentrat za rastvor za infuziju
druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - gemcitabin - koncentrat za rastvor za infuziju - 1000mg/100ml
gemcitabin ebewe 200mg/20ml koncentrat za rastvor za infuziju
druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - gemcitabin - koncentrat za rastvor za infuziju - 200mg/20ml
gemnil 1000mg prašak za rastvor za infuziju
"osmi red-d" d.o.o. podgorica - gemcitabin - prašak za rastvor za infuziju - 1000mg
gemnil 200mg prašak za rastvor za infuziju
"osmi red-d" d.o.o. podgorica - gemcitabin - prašak za rastvor za infuziju - 200mg
taxotere 20 mg/1 ml 20 mg/1 ml koncentrat za rastvor za infuziju
sanofi d.o.o. - docetaksel - koncentrat za rastvor za infuziju - 20 mg/1 ml - 1 ml koncetrata za rastvor za infuziju sadrži: 20 mg docetaksela (u obliku docetaksel trihidrata)
taxotere 80 mg/4 ml 20 mg/1 ml koncentrat za rastvor za infuziju
sanofi d.o.o. - docetaksel - koncentrat za rastvor za infuziju - 20 mg/1 ml - 1 ml koncetrata za rastvor za infuziju sadrži: 20 mg docetaksela (u obliku docetaksel trihidrata)
tecentriq
roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastična sredstva - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq u monoterapiji namijenjen za liječenje odraslih bolesnika s lokalno-uobičajena ili metastatskih НМРЛ nakon što je ranije kemoterapije. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq u monoterapiji namijenjen za liječenje odraslih bolesnika s lokalno-uobičajena ili metastatskih НМРЛ nakon što je ranije kemoterapije. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.
abraxane 5 mg/1 ml prašak za disperziju za infuziju
amicus pharma d.o.o. - paklitaksel - prašak za disperziju za infuziju - 5 mg/1 ml - 1 ml disperzije sadrži: 5 mg paklitaksela